Due: May 30, 2025
The JPEO-CBRND is interested in late-stage development of host-directed therapeutics or repurposing of United States Food and Drug Administration (FDA) licensed therapeutics that are threat-agnostic with the potential for activity across viral or toxin families. The candidate(s) should have demonstrated activity targeting the patient’s immune response to infection or illness caused by viruses or toxins. The ideal candidate would be a small molecule with enhanced stability that can be easily administered by either ingestion, inhalation or intramuscular injection. Development and clinical testing of vaccines will not be considered in this request.
Responding to this opportunity requires membership in the Medical CBRN Defense Consortium. This Consortium releases numerous solicitations throughout the year, so even if this opportunity may not end up being right for you, we strongly encourage you to join, so you are ready for the next opportunity.
Complete the form below and a program representative will reach out to you shortly to support you through the process.